12:00 AM
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Proellex: Phase II start

Repros said FDA converted a full clinical hold on additional trials of oral Proellex to a partial hold to allow the company to conduct a placebo-controlled Phase II trial evaluating low-dose Proellex. The company believes data from the Phase II trial, which will evaluate 6 and 12 mg Proellex for 4 months in 90 patients,...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >